苏州赛分科技股份有限公司 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 股东会议事规则 第一章 总则 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第一条 为规范苏州赛分科技股份有限公司（以下简称"公司"）行为，保 证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司治理准则 （2025修订）》和《上市公司股东会规则（2025年修订）》以及其他法律、行政 法规和《苏州赛分科技股份有限公司章程》（以下简称"公司章程"）的规定， 制定本规则。 第三条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的6个月内举行。临时股东会不定期召开，出现下列 情况之一的，公司应当在事实发生之日起2个月内召开临时股东会： （一）董事人数不足《公司法》规定人数或公司章程规定人数的三分之二时； （二）公司未弥补的亏损达 ...

第一条 为了进一步完善公司法人治理结构，保证苏州赛分科技股份有限公司 （以下简称"公司"）所有股东充分行使权利，根据中国证监会《上市公司治理准 则》、《上海证券交易所科创板股票上市规则》、《苏州赛分科技股份有限公司章 程》（以下简称"《公司章程》"）及其他有关规定，制定本实施细则。 第二条 本实施细则所指的累积投票制，是指股东会在选举两名以上（含两名） 董事时采用的一种投票方式。即公司选举董事时，每位股东所持有的每一股份都拥 有与应选董事总人数相等的投票权，股东既可以用所有的投票权集中选举一人，也 可以分散选举数人，最后按得票多少依次决定董事人选。 第三条 本实施细则所称"董事"包括独立董事和非独立董事。 第四条 股东会选举产生的董事人数及结构应符合公司章程的规定。 苏州赛分科技股份有限公司 累积投票制实施细则 第五条 股东会对董事候选人进行表决前，会议主持人应明确告知与会股东对候 选董事实行累积投票方式，股东会工作人员应该置备适合实行累积投票方式的选票。 董事会秘书应对累积投票方式、选票填写方法做出说明和解释。 第六条 运用累积投票制选举公司董事的具体表决办法如下： （一）累积投票制的票数计算法 1. 每位 ...

苏州赛分科技股份有限公司 2024 年度独立董事述职报告 作为苏州赛分科技股份有限公司（以下简称"公司"）的独立董事，本人严 格按照《公司法》《证券法》《上海证券交易所科创板股票上市规则》以及《公司 章程》《独立董事工作制度》等规定，在 2024 年的工作中，本着对公司和全体股 东诚信和勤勉的原则，以关注和维护全体股东的利益为中心，认真审阅董事会提 交的各项议案，积极出席公司股东大会、董事会及各专门委员会会议，参与公司 重大事项的研究、讨论、分析，详细了解公司内部运行情况，并依照法律法规对 相关事项发表了独立意见，忠实履行了独立董事的职责，维护了公司与全体股东 的利益。现将本人 2024 年度的履职情况报告如下： 二、2024 年度履职情况 （一）出席董事会、股东大会情况 （二）参加董事会专门委员会会议情况 报告期，作为董事会薪酬与考核委员会召集人、董事会提名委员会委员、董 事会战略委员会委员，严格按照有关法律法规以及公司制度，出席了相关会议， 专门委员会参会情况如下： | 专门委员会类别 | 报告期召开次数 | 应参加次数 | 亲自参加次数 | 委托出席次数 | | --- | --- | --- | -- ...

苏州赛分科技股份有限公司 （二）独立性情况说明 作为公司独立董事，本人具有《上市公司独立董事管理办法》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规所规定的任 职资格及独立性要求，能够确保客观、独立的专业判断，不存在影响独立性的情 况。 二、2024 年度履职情况 （一）出席董事会、股东大会情况 （二）参加董事会专门委员会会议情况 2024 年度独立董事述职报告 作为苏州赛分科技股份有限公司（以下简称"公司"）的独立董事，本人严 格按照《公司法》《证券法》《上海证券交易所科创板股票上市规则》以及《公司 章程》《独立董事工作制度》等规定，在 2024 年的工作中，本着对公司和全体股 东诚信和勤勉的原则，以关注和维护全体股东的利益为中心，认真审阅董事会提 交的各项议案，积极出席公司股东大会、董事会及各专门委员会会议，参与公司 重大事项的研究、讨论、分析，详细了解公司内部运行情况，并依照法律法规对 相关事项发表了独立意见，忠实履行了独立董事的职责，维护了公司与全体股东 的利益。现将本人 2024 年度的履职情况报告如下： 一、独立董事基本情况 （一）个人履历 彭淑贞：女，中国国籍，南 ...

第二条 本制度所指募集资金是指公司通过公开发行证券（包括首次发行 股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券、 发行权证等）以及非公开发行股票向投资者募集用于特定用途的资金，但不包 括公司实施股权激励计划募集的资金。 第三条 募集资金到位后，公司应及时办理验资手续，由符合《证券法》 规定的会计师事务所出具验资报告，并按照募股说明书或募集说明书所承诺的 募集资金使用计划，组织募集资金的使用工作。 苏州赛分科技股份有限公司 募集资金管理制度 第一章 总则 第一条 为了规范苏州赛分科技股份有限公司（以下简称"公司"）募集 资金的管理和使用，切实保护投资者的权益，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上海证券交易所科创板股票上市规则》《上市公司监管指引第 2 号--上市公司募集资金管理和使用的监管要求》等有关法律、法规、规范性文 件和《苏州赛分科技股份有限公司章程》（以下简称"《公司章程》"）的要 求，结合公司的实际情况，特制定本制度。 第四条 公司董事会应当确保本制度的有效实施。募集资金投资项目通过 公司的子公司或公 ...

苏州赛分科技股份有限公司 对外担保管理制度 （三）公司所属全资公司、持股超过50%的子公司； 第二条 公司对外担保应当遵循合法、审慎、互利、安全的原则，全体董事 及高级管理人员应审慎对待和严格控制对外担保产生的债务风险，并对违规或失 当的对外担保产生的损失依法承担连带责任。控股股东及其他关联方不得强制公 司为他人提供担保。 第三条 本制度适用于公司（包括公司的全资、控股子公司）为他人提供下 列担保的行为：被担保企业因向金融机构贷款、票据贴现、融资租赁等原因向公 司申请为其提供担保，其中包括公司对控股子公司的担保。 第四条 公司对外提供担保，应根据《股票上市规则》及中国证监会的有关 规定披露有关信息。 第二章 对外担保对象 第五条 公司可以为具有独立资格且具有下列条件之一的单位担保： （一）因公司业务需要的互保单位； （二）与公司有现实或潜在重要业务关系的单位； 第一章 总则 第一条 为规范苏州赛分科技股份有限公司（以下简称"公司"）对外担保行 为，控制和降低担保风险，保证公司资产安全，根据《中华人民共和国民法典》 （以下简称"《民法典》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司治理 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥83,587,089.19, representing an increase of 8.87% compared to ¥76,776,735.66 in the same period last year[3]. - The net profit attributable to shareholders decreased by 1.02% to ¥23,712,621.06 from ¥23,957,060.85 year-on-year[3]. - The net profit for Q1 2025 is CNY 23,880,736.67, a decrease of 2.55% compared to CNY 24,507,260.57 in Q1 2024[15]. - The company reported a comprehensive income total of CNY 23,828,821.34 for Q1 2025, compared to CNY 24,697,375.86 in Q1 2024, indicating a decrease of about 3.5%[17]. - Basic earnings per share for Q1 2025 is CNY 0.0593, down from CNY 0.0654 in Q1 2024, representing a decline of approximately 9.3%[17]. Cash Flow and Liquidity - The net cash flow from operating activities dropped significantly by 97.56% to ¥396,039.16, down from ¥16,229,892.37 in the previous year[3]. - The cash flow from operating activities shows a net increase of CNY 396,039.16, significantly lower than CNY 16,229,892.37 in the same period last year[18]. - The company generated CNY 21,547,815.06 in net cash flow from investing activities in Q1 2025, a significant improvement compared to a negative cash flow of CNY 23,686,987.66 in Q1 2024[19]. - The financing activities generated a net cash flow of CNY 175,038,543.72 in Q1 2025, compared to a negative cash flow of CNY 2,044,558.45 in Q1 2024, indicating a strong improvement in financing[19]. - Cash and cash equivalents increased to ¥299,817,279.15 from ¥103,080,898.09, representing a growth of 189.5%[10]. Assets and Liabilities - The total assets at the end of the reporting period increased by 14.94% to ¥1,358,984,272.87 from ¥1,182,310,293.37 at the end of the previous year[3]. - Current assets as of March 31, 2025, totaled ¥785,539,359.11, a significant increase of 33.0% from ¥590,390,238.19 at the end of 2024[10]. - Total assets reached ¥1,358,984,272.87, an increase of 15.0% from ¥1,182,310,293.37 at the end of 2024[12]. - Total liabilities decreased to ¥70,716,025.89 from ¥84,269,862.24, a reduction of 16.1%[12]. - Shareholders' equity increased to ¥1,288,268,246.98, up 17.3% from ¥1,098,040,431.13 at the end of 2024[12]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥53,628,737.30, up 14.7% from ¥46,742,557.97 in Q1 2024[14]. - Operating costs included ¥21,613,466.86 in operating expenses, which rose 20.5% from ¥18,010,478.67 in Q1 2024[14]. - The total tax expenses for Q1 2025 are CNY 3,984,561.36, an increase from CNY 3,010,143.26 in Q1 2024, representing a rise of approximately 32.3%[15]. Research and Development - Research and development expenses totaled ¥11,284,285.02, which is an increase of 10.23% compared to ¥10,237,437.10 in the same period last year[3]. - R&D expenses accounted for 13.50% of operating revenue, up from 13.33% year-on-year, indicating a slight increase in investment in innovation[3]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,961, indicating a stable shareholder base[7]. - The weighted average return on equity decreased by 0.41 percentage points to 1.96% from 2.37% in the previous year[3].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 25% year-over-year growth[18]. - The company achieved operating revenue of CNY 315.46 million in 2024, representing a year-on-year growth of 28.65%[26]. - Net profit attributable to shareholders reached CNY 85.16 million, a 62.25% increase compared to the previous year[27]. - Basic earnings per share increased by 62.29% to CNY 0.2324, while diluted earnings per share also rose by the same percentage[25]. - The company reported a net cash inflow from operating activities of CNY 66.01 million, up 52.22% year-on-year[27]. - The company's total assets at the end of 2024 were CNY 1.18 billion, reflecting a 7.29% increase from the previous year[26]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[18]. - The net profit attributable to the parent company was 85.16 million yuan, a year-on-year increase of 62.25%, with a net profit margin significantly improved due to operational leverage[37]. Research and Development - The company is investing in R&D, allocating 10% of its revenue towards developing advanced separation technologies[16]. - Research and development expenses accounted for 13.59% of operating revenue, a decrease of 4.44 percentage points from the previous year[25]. - The R&D team has over 20 years of experience, developing advanced techniques in key areas such as microsphere synthesis and functional biomolecule synthesis, which are crucial for maintaining a competitive edge against international rivals[82]. - The company has introduced 34 new patent applications in 2024, including 28 invention patents, and has a total of 75 effective authorized patents, of which 24 are invention patents[52]. - The company has developed unique core technologies in chromatography medium preparation, which are critical for maintaining its competitive edge in the market[182]. Market Expansion and Strategy - Market expansion plans include entering the Southeast Asian market, targeting a 10% market share within the next two years[18]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in biopharmaceuticals[18]. - The company has established partnerships with three major pharmaceutical firms to co-develop new therapeutic solutions[18]. - The company is actively promoting the replacement of imported materials with domestic alternatives[200]. - The company has established strategic partnerships with leading pharmaceutical companies such as Roche, Eli Lilly, and Pfizer, enhancing its innovation capabilities in drug discovery and scientific research[178]. Production and Operational Efficiency - The company maintained a 100% production plan achievement rate and order delivery rate at its Yangzhou factory during the reporting period[43]. - The Yangzhou production base commenced operations in 2021, with an annual capacity of 24,760 liters and a single batch capacity of 500 liters, making it one of the few companies in the domestic chromatography medium industry with large-scale production capabilities[63]. - The company plans to expand its production capacity to a total of 224,760 liters per year after the completion of the second phase of the Yangzhou project, further enhancing its production capabilities[179]. - The company has a large-scale production base in Yangzhou covering 41,405 square meters, with a biopharmaceutical chromatography medium capacity of 24,760 liters, ensuring stable supply for downstream drug production[179]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[3]. - The company has disclosed potential risks in the management discussion and analysis section of the report[3]. - The company is facing risks related to potential talent loss in its high-level technical team, which is essential for ongoing innovation and development[184]. - The company faces a potential asset impairment loss of up to 8.71 million yuan and 12.15 million yuan in 2025 and 2026, respectively, if it fails to secure additional orders[190]. - The company is exposed to risks from policy changes in the pharmaceutical industry, which could slow down demand for its chromatography products[193]. Product Development and Innovation - New product launches included a novel chromatography medium that is expected to enhance purification efficiency by 15%[16]. - The company has developed a new seed swelling polymerization technology that simplifies the production process, increases efficiency, and reduces solvent and additive usage, leading to lower production costs compared to traditional methods[141]. - The company has created a core-shell chromatography medium that combines multiple separation mechanisms, breaking the long-standing market monopoly[174]. - The company has developed multiple downstream purification platform technologies across various segments, including antibodies and recombinant proteins, enabling faster adaptation for new project processes[157]. - The company has developed a unique rSPA protein sequence for affinity chromatography media, enhancing alkaline resistance and dynamic capacity[175]. Customer and Market Engagement - The company employs a direct sales model complemented by distribution for domestic sales, utilizing industry exhibitions, customer visits, and internet marketing to secure orders and maintain long-term partnerships with major pharmaceutical companies[64]. - The company has established a comprehensive sales management system, including strict regulations on contract signing, settlement methods, credit policies, and return policies[67]. - The company’s overseas business revenue accounted for 23.02% of total revenue, highlighting its global market presence[185]. - The accounts receivable balance at the end of the reporting period was 96.90 million yuan, representing 30.72% of total revenue, with a collection rate of 57.13% as of March 31, 2025[189]. Industry Trends and Market Outlook - The chromatography medium market in China is projected to reach 13.6 billion CNY in 2024, with an expected growth to 20.3 billion CNY by 2026, reflecting a compound annual growth rate (CAGR) of 22.17% from 2024 to 2026[101]. - The global chromatography medium market is expected to reach 7.5 billion USD in 2024 and grow to 9 billion USD by 2026, with a CAGR of 9.54%[102]. - The demand for chromatography products is increasing due to the rising clinical needs and the rapid development of innovative biopharmaceuticals[118]. - The domestic biopharmaceutical industry is enhancing its R&D capabilities, leading to higher demands for purification processes and creating new business opportunities for chromatography media[134]. - The global biopharmaceutical market grew from $220.2 billion in 2016 to $297.9 billion in 2020, with a CAGR of 7.85%[112].

董事会 根据《上市公司独立董事管理办法》《上市公司治理准则》《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等相关法律法规及《公司章程》等公司管理制度有关规定，苏州赛 分科技股份有限公司（以下简称"公司"）董事会就公司在任独立董事彭淑贞女 士、梁永伟先生、徐锋先生的独立性情况进行评估并出具如下专项意见： 经核查独立董事彭淑贞女士、梁永伟先生、徐锋先生的任职经历及已经签署 的相关自查文件，确认上述人员未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，因此，公司董事会认为，公司独立董 事符合《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》中对独立董事独立性的相关要求。 苏州赛分科技股份有限公司 苏州赛分科技股份有限公司 2024 年度董事会对独立董事独立性自查情况的专项报告 2025 年 4 月 28 日 1 ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-015 苏州赛分科技股份有限公司 关于取消公司监事会及修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第二届董事会 2025 年第三次会议和第二届监事会 2025 年第二次会议，审议 通过《关于取消公司监事会及修订<公司章程>的议案》,本议案尚需提交公司 2024 年年度股东大会审议。现将相关情况公告如下： 一、关于取消公司监事会的情况 根据《中华人民共和国公司法（2023 年修订）》《上市公司章程指引（2025 年修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等法律法规和规范性文件的最新规定，结合公司实际情况，现取消公司监事会， 监事会的职权由董事会审计委员会行使，《监事会议事规则》等监事会相关制度 相应废止。 二、关于修改《公司章程》的情况 鉴于上述情况，结合相关法律法规的要求，公司拟对《苏州赛分科技股份 有限公司章程》 ...